Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.30, $0.53 better than the analyst estimate of $4.77. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion.

GUIDANCE:

Jazz Pharmaceuticals sees FY2024 EPS of $19.20-$20.30, versus the consensus of $18.51. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.1 billion, versus the consensus of $4.05 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.